Kevin Templar
General Practice · Las Vegas, NVNPI 1518000538
Payments from drug & device makers
Across 65 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$626
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$217
- Novo Nordisk$167
- Collegium Pharmaceutical, Inc.$167
- AstraZeneca$142
- Pfizer$88
- plus $459 from 14 others
What the payments were for
- Food & beverage$1,865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $626 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $217 |
| Novo Nordisk | 11 | $167 |
| Collegium Pharmaceutical, Inc. | 3 | $167 |
| AstraZeneca | 2 | $142 |
| Pfizer | 2 | $88 |
| Biodelivery Sciences International, Inc. | 1 | $73 |
| Biohaven Pharmaceuticals, Inc. | 5 | $61 |
| GRT US Holding, Inc. | 1 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $33 |
| Bayer | 1 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Boston Scientific | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $17 |
| Exact Sciences | 1 | $14 |
| Intuitive Surgical | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,865 in reported general payments places this provider in the 75th percentile of 910 general practice providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $39,696 |
| FarxigaDapagliflozin Propanediol | 12 | $20,115 |
| VascepaIcosapent Ethyl | 12 | $11,045 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,624 |
| Rosuvastatin Calcium | 191 | $2,124 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,528 |
| Metoprolol Succinate | 77 | $938 |
| Levothyroxine Sodium | 73 | $861 |
| Losartan Potassium | 92 | $731 |
| Piroxicam | 28 | $502 |
| Metformin Hcl | 63 | $357 |
| Omeprazole | 37 | $333 |
| Lisinopril | 51 | $310 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 25 | $304 |
| Pantoprazole Sodium | 42 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $167 | $39,69623 claims |
| AstraZenecaFarxiga | $142 | $20,11512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 910 general practice providers in Nevada.
Other general practice in Las Vegas
- Johnathan WhiteLas Vegas$1.5M
- Tawni ChristensenLas Vegas$1.4M
- Michael WebbersonLas Vegas$138K
- Yeong KimLas Vegas$82K
- Rewadee MeevasinLas Vegas$45K
- Joseph WillardsenLas Vegas$41K
- Arthur TomaroLas Vegas$37K
- Ali ShahrestaniLas Vegas$26K
- Shamshudin KheraniLas Vegas$22K
- Jong KimLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.